Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

15 trials with published results (8%)

Research Maturity

58 completed trials (30% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.1%

6 terminated out of 192 trials

Success Rate

90.6%

+4.1% vs benchmark

Late-Stage Pipeline

17%

32 trials in Phase 3/4

Results Transparency

26%

15 of 58 completed with results

Key Signals

15 with results91% success

Data Visualizations

Phase Distribution

160Total
Not Applicable (74)
Early P 1 (1)
P 1 (15)
P 2 (38)
P 3 (21)
P 4 (11)

Trial Status

Recruiting67
Completed58
Not Yet Recruiting36
Active Not Recruiting8
Enrolling By Invitation7
Unknown7

Trial Success Rate

90.6%

Benchmark: 86.5%

Based on 58 completed trials

Clinical Trials (192)

Showing 20 of 20 trials
NCT07727005Not ApplicableNot Yet RecruitingPrimary

Effectiveness of Clustered Versus Tapered Repetitive Transcranial Magnetic Stimulation (rTMS) as Maintenance Therapy Following Successful Acute rTMS Treatment in Patients With Depressive Syndrome

NCT07728253Not ApplicableNot Yet RecruitingPrimary

Probiotic IBNI617 for Moderate to Severe Depression: A Randomized Controlled Trial

NCT07712159Not ApplicableNot Yet RecruitingPrimary

Temporal Interference Transcranial Alternating Current Stimulation for Major Depressive Disorder and Generalized Anxiety Disorder

NCT07533773Not ApplicableRecruitingPrimary

Investigating Functional Changes in the Frontotemporal Cortex of Patients With Major Depressive Disorder Following Electroconvulsive Therapy or Magnetic Seizure Therapy Using Functional Near-infrared Spectroscopy (fNIRS)

NCT07610473Phase 2RecruitingPrimary

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

NCT07284667Phase 2RecruitingPrimary

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

NCT07139834Phase 1RecruitingPrimary

Pattern Separation in Major Depressive Disorder

NCT07065240Phase 2RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

NCT07161700Phase 2Enrolling By InvitationPrimary

An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

NCT07043738Not ApplicableNot Yet RecruitingPrimary

Imaging- vs. Scalp-Targeted Accelerated TMS for Depression: The Number Needed to Scan Trial

NCT07562191Phase 2Recruiting

Inhaled DMT for Major Depressive Disorder

NCT07696871Phase 1RecruitingPrimary

Cannabidiol Oil for Treatment-Resistant Major Depression

NCT06746155RecruitingPrimary

Predictors of Relapse in Major Depressive Disorder (PERFORM-D)

NCT07059143Not ApplicableCompletedPrimary

6 Weeks Right-Amygdala TIS for Depression

NCT07694076Not ApplicableRecruitingPrimary

Repeated Real-time Biofeedback With 7-Tesla MRI for Treatment of Depression

NCT06624137Terminated

Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics

NCT07032428Not ApplicableNot Yet Recruiting

Efficacy of kTMP, a Novel Non-invasive Brain Stimulation Method, for the Treatment of Anhedonia

NCT06792136Phase 2CompletedPrimary

A Study of ONO-1110 in Patients With Major Depressive Disorder

NCT07685964Phase 1Not Yet Recruiting

Pregnenolone for Cannabis Use Disorder and Depression

NCT07300969Phase 2RecruitingPrimary

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

Scroll to load more

Research Network

Activity Timeline